Please assess the completion status of the following clinical trial:

Trial Title: A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Major Patient~2. Patient with a diagnosis of Alzheimer's disease according to DSM-IV and NINCDS-ADRDA criteria.~3. Patient at a moderate stage of the disease: Score at CDR (Clinical Dementia Rating Scale) between 0.5 inclusive and 2 inclusive and MMS score greater than or equal to 10 and lower strictly at 27~4. Lexical-semantic disorder~5. Treatment with pro-cognitive drugs at stable doses for at least 3 months,~6. Speech therapy in progress (2 or 3 sessions per week)~7. Patient with free and informed consent~8. Affiliated to the Health care system~9. Native french speaker,~10. Attendance of a caregiver.~For the early onset group, patients should have started the disease before 65 years of age. The randomization will be stratified according to age (\<65 years or\> 65 years), enabling to include 2 groups of identical size of young AD (Alzheimer Disease) and Late (Alzheimer Disease) patients, each half distributed in the tablet or control group.~Exclusion Criteria:~1. Other known neurological disease or general illness or major psychic problems that may interfere with cognitive functioning,~2. Patient under guardianship or curatorship~3. Confusion,~4. Cerebral MRI (or scanner for contraindication to MRI), obtained in the context of routine care compatible with a pathological process other than that related to Alzheimer's disease. A discrete or moderate leukoaraiosis (stages 1 and 2 of Fazekas) will not be considered as a criterion of non-inclusion.~5. Uncorrected hearing or visual impairment~6. Inclusion in another intervention protocol.~7. Participation in an additional stimulation workshop

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tablet group (Type: EXPERIMENTAL): Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
- Control group (Type: ACTIVE_COMPARATOR): Patients will continue their usual care (1 or more sessions of weekly speech therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).